Alvaro Cobo-Calvo

List of Publications by Year
in descending order

36 papers	1,953 citations	394286 19 h-index	315616 38 g-index
40 all docs	40 docs citations	40 times ranked	1792 citing authors

#	Article	IF	Citations
1	Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 950-957.	1.4	7
2	Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre. Journal of Neurology, 2022, 269, 1764-1772.	1.8	5
3	Herpes simplex encephalitis in the context of immune checkpoint inhibitors: a complex interplay. Acta Neurologica Belgica, 2022, 122, 823-825.	0.5	3
4	Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, e1143.	3.1	17
5	Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?. Multiple Sclerosis Journal, 2022, 28, 1138-1145.	1.4	11
6	The kappa free light chain index and oligoclonal bands have a similar role in the McDonald criteria. Brain, 2022, 145, 3931-3942.	3.7	12
7	Diagnostic value of bright spotty lesions on MRI after a first episode of acute myelopathy. Journal of Neuroradiology, 2021, 48, 28-36.	0.6	24
8	COVID‐19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response. European Journal of Neurology, 2021, 28, 3384-3395.	1.7	111
9	Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease. Annals of Neurology, 2021, 89, 30-41.	2.8	123
10	Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome. Neurology, 2021, 97, e1641-e1652.	1.5	35
11	Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurology, The, 2021, 20, 762-772.	4.9	261
12	Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study. Multiple Sclerosis Journal, 2020, 26, 936-944.	1.4	37
13	MOG-antibody-associated disease is different from MS and NMO and should be considered as a distinct disease entity – No. Multiple Sclerosis Journal, 2020, 26, 274-276.	1.4	6
14	Purified IgG from aquaporin-4 neuromyelitis optica spectrum disorder patients alters blood-brain barrier permeability. PLoS ONE, 2020, 15, e0238301.	1.1	11
15	Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. Multiple Sclerosis and Related Disorders, 2020, 44, 102251.	0.9	110
16	Risk factors for academic difficulties in children with myelin oligodendrocyte glycoprotein antibody‐associated acute demyelinating syndromes. Developmental Medicine and Child Neurology, 2020, 62, 1075-1081.	1.1	13
17	Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. Journal of Neuroinflammation, 2019, 16, 134.	3.1	115
18	Myelin oligodendrocyte glycoprotein antibody associated disease: about the importance of diagnostic assays and selection of the target population in retrospective studies. European Journal of Neurology, 2019, 26, e58-e59.	1.7	3

#	Article	IF	Citations
19	Paraneoplastic neuromyelitis optica and ovarian teratoma: A case series. Multiple Sclerosis and Related Disorders, 2019, 31, 97-100.	0.9	19
20	Clinical spectrum of central nervous system myelin oligodendrocyte glycoprotein autoimmunity in adults. Current Opinion in Neurology, 2019, 32, 459-466.	1.8	38
21	The Balance in T Follicular Helper Cell Subsets Is Altered in Neuromyelitis Optica Spectrum Disorder Patients and Restored by Rituximab. Frontiers in Immunology, 2019, 10, 2686.	2.2	25
22	Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults. Journal of Neurology, 2019, 266, 806-815.	1.8	47
23	Cranial nerve involvement in patients with MOG antibody–associated disease. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e543.	3.1	53
24	Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults. Neurology, 2018, 90, e1858-e1869.	1.5	401
25	Feasibility and Effects of Structured Physical Exercise Interventions in Adults with Relapsing-Remitting Multiple Sclerosis: A Pilot Study. Journal of Sports Science and Medicine, 2018, 17, 426-436.	0.7	3
26	MOG antibody-related disorders: common features and uncommon presentations. Journal of Neurology, 2017, 264, 1945-1955.	1.8	119
27	Neuromyelitis optica spectrum disorders. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e225.	3.1	134
28	Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis. Journal of Neuroimmunology, 2016, 299, 112-117.	1.1	43
29	Leukocyte adhesion molecule dynamics after Natalizumab withdrawal in Multiple Sclerosis. Clinical Immunology, 2016, 171, 18-24.	1.4	6
30	MxA mRNA expression as a biomarker of interferon beta response in multiple sclerosis patients. Journal of Neuroimmunology, 2016, 291, 73-77.	1.1	3
31	Adaptive natural killer cell response to cytomegalovirus and disability progression in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 741-752.	1.4	26
32	Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: Clinical and prognostic implications. Multiple Sclerosis Journal, 2016, 22, 312-319.	1.4	79
33	Effectiveness of Natalizumab in Patients with Highly Active Relapsing Remitting Multiple Sclerosis. European Neurology, 2015, 73, 220-229.	0.6	12
34	Etiologic Spectrum and Prognosis of Longitudinally Extensive Transverse Myelopathies. European Neurology, 2014, 72, 86-94.	0.6	22
35	Optic Neuritis in the Setting of NMDA Receptor Encephalitis. Journal of Neuro-Ophthalmology, 2014, 34, 316-319.	0.4	6
36	Baseline MxA mRNA Expression Predicts Interferon Beta Response in Multiple Sclerosis Patients. PLoS ONE, 2014, 9, e112758.	1.1	11